OverviewSuggest Edit

Nektar Therapeutics is a stage-clinical biopharmaceutical company. The Сompany develops new drug candidates by applying its proprietary PEGylation and advanced polymer conjugate technologies to modify the chemical structure of substances. It is a technology supplier to a number of pharmaceutical companies including Affymax, Amgen, Merck, Pfizer and UCB Pharma, etc. Nektar Therapeuticsэ R&D pipeline of new investigational drugs includes treatments for cancer, auto-immune disease, and chronic pain.

TypePublic
Founded1990
HQSan Francisco, CA, US
Websitenektar.com
Employee Ratings3.3

Latest Updates

Employees (est.) (Dec 2018)618(+22%)
Revenue (FY, 2019)$114.6 M(-90%)
Share Price (Jan 2021)$17 (-4%)
Cybersecurity ratingAMore

Key People/Management at Nektar Therapeutics

Jeff Ajer

Jeff Ajer

Director
Robert B. Chess

Robert B. Chess

Chairman of the Board
Gil M. Labrucherie

Gil M. Labrucherie

Chief Operating Officer and Chief Financial Officer
R. Scott Greer

R. Scott Greer

Director
Myriam J. Curet

Myriam J. Curet

Director
Kevin Brodbeck

Kevin Brodbeck

Senior Vice President of Manufacturing
Show more

Nektar Therapeutics Office Locations

Nektar Therapeutics has offices in San Francisco, Huntsville and Secunderabad
San Francisco, CA, US (HQ)
455 Mission Bay Boulevard South, San Francisco
Huntsville, AL, US
1112 Church St NW
Secunderabad, IN
Shamirpet, Secunderabad
Show all (3)

Nektar Therapeutics Financials and Metrics

Nektar Therapeutics Revenue

Embed Graph
View revenue for all periods
Nektar Therapeutics's revenue was reported to be $114.62 m in FY, 2019
USD

Revenue (Q3, 2020)

5.7m

Market capitalization (15-Jan-2021)

3.0b

Closing stock price (15-Jan-2021)

17.0

Cash (30-Sept-2020)

55.8m

EV

3.1b
Nektar Therapeutics's current market capitalization is $3 b.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014Y, 2015FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

71.5m81.2m148.9m200.7m230.8m230.8m165.4m307.7m1.2b114.6m

Revenue growth, %

35%15%(28%)

Cost of goods sold

21.9m30.4m38.5m28.5m34.1m34.1m30.2m30.5m24.4m21.4m

Gross profit

49.6m50.8m110.4m172.2m196.7m196.7m135.2m277.2m1.2b93.2m
Quarterly
USDQ1, 2011

Financial Leverage

2.5 x
Show all financial metrics

Nektar Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

93/100

SecurityScorecard logo

Nektar Therapeutics Online and Social Media Presence

Embed Graph

Nektar Therapeutics News and Updates

Nektar Therapeutics Reports Third Quarter 2020 Financial Results

SAN FRANCISCO, Nov. 5, 2020 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today reported financial results for the third quarter ended September 30, 2020. Cash and investments in marketable securities at September 30, 2020 were approximately $1.2 billion as compared to $1.6 billion...

Nektar Therapeutics Announces Phase 1b Clinical Study to Evaluate Bempegaldesleukin for Treatment of Patients Diagnosed with Mild COVID-19

SAN FRANCISCO, Oct. 27, 2020 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced that it has received FDA clearance for an Investigational New Drug (IND) application for its investigational IL-2 pathway agent, bempegaldesleukin (BEMPEG, NKTR-214), to be evaluated in a Phase...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR

NEW YORK, Jan. 24, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ: NKTR). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980. The...

Thinking about buying stock in Bilibili, Microsoft, Nio, Nektar Therapeutics, or NVIDIA?

NEW YORK, Jan. 13, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BILI, MSFT, NIO, NKTR, and NVDA. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Nektar Therapeutics Presents New Clinical and Preclinical Data from its Immuno-Oncology Pipeline at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting

SAN FRANCISCO, Nov. 9, 2019 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced the presentation of five clinical and preclinical data abstracts focused on its immuno-oncology portfolio at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting. New clinical...

How Bempegaldesleukin Woes Have Impacted Nektar Therapeutics

Nektar Therapeutics (NASDAQ: NKTR), a biopharmaceutical company based in San Francisco, is focused on discovering and developing medicines in areas that include cancer, autoimmune disease, and chronic pain. The stock is down by about 20% over the last month and by almost 50% in the last quarter ...
Show more

Nektar Therapeutics Blogs

Nektar Therapeutics' President and CEO, Howard Robin, to Present at the 39th Annual J.P. Morgan Virtual Healthcare Conference

Nektar Therapeutics' President and CEO, Howard Robin, to Present at the 39th Annual J.P. Morgan Virtual Healthcare Conference Content Import Wed, 01/06/2021 - 17:01 Nektar Therapeutics' President and CEO, Howard Robin, to Present at the 39th Annual J.P. Morgan Virtual Healthcare Conference…

Nektar Appoints Dr. Brian Kotzin as Interim Chief Medical Officer and Head of Development

Nektar Appoints Dr. Brian Kotzin as Interim Chief Medical Officer and Head of Development jamescalvin.ve… Tue, 01/05/2021 - 16:20 Nektar Appoints Dr. Brian Kotzin as Interim Chief Medical Officer and Head of Development Jan 5, 2021 This release is a backfill f…

Nektar Therapeutics Announces Agreement with Healthcare Royalty to Sell ADYNOVATE® and MOVANTIK® Royalties for $150 Million

SAN FRANCISCO , Dec. 22, 2020 /PRNewswire/ --  Nektar Therapeutics (NASDAQ: NKTR) today announced that it agreed to sell to entities managed by Healthcare Royalty Management, LLC (HCR) its royalties on future sales of ADYNOVATE, under Nektar's agreement with Baxalta Incorporated, a Takeda company,

Nektar Therapeutics Announces Dosing of First Patients in Phase 1/2 Study of its IL-15 Agonist, NKTR-255, in Combination with Cetuximab in Patients with Head and Neck Squamous Cell Carcinoma or Colorectal Cancer

Nektar Therapeutics Announces Dosing of First Patients in Phase 1/2 Study of its IL-15 Agonist, NKTR-255, in Combination with Cetuximab in Patients with Head and Neck Squamous Cell Carcinoma or Colorectal Cancer Content Import Tue, 12/15/2020 - 08:31 Nektar Therapeutics Announces Dosing of…

Nektar Therapeutics Announces Presentation of Preclinical Data for NKTR-255, its Novel IL-15 Agonist, at the American Society of Hematology (ASH) 2020 Annual Meeting

SAN FRANCISCO , Dec. 7, 2020 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced two nonclinical data presentations for NKTR-255, its IL-15 pathway agonist, at the 62 nd   American Society of Hematology (ASH) Annual Meeting. The presentations include an oral presentation of

Nektar Therapeutics Presents New Data from Its Immuno-Oncology Pipeline at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Updated Clinical Data for Patients with Metastatic Melanoma Treated in PIVOT-02 Study of Bempegaldesleukin with Nivolumab Show Durable Clinical Benefit with Median Progression-Free Survival of 30.9 Months   New Clinical Data Presentations for NKTR-255, a Novel IL-15 Agonist, and NKTR-262, a TLR 7/8
Show more

Nektar Therapeutics Frequently Asked Questions

  • When was Nektar Therapeutics founded?

    Nektar Therapeutics was founded in 1990.

  • Who are Nektar Therapeutics key executives?

    Nektar Therapeutics's key executives are Jeff Ajer, Robert B. Chess and Gil M. Labrucherie.

  • How many employees does Nektar Therapeutics have?

    Nektar Therapeutics has 618 employees.

  • What is Nektar Therapeutics revenue?

    Latest Nektar Therapeutics annual revenue is $114.6 m.

  • What is Nektar Therapeutics revenue per employee?

    Latest Nektar Therapeutics revenue per employee is $185.5 k.

  • Who are Nektar Therapeutics competitors?

    Competitors of Nektar Therapeutics include Mirati Therapeutics, CytomX Therapeutics and Calithera Biosciences.

  • Where is Nektar Therapeutics headquarters?

    Nektar Therapeutics headquarters is located at 455 Mission Bay Boulevard South, San Francisco, San Francisco.

  • Where are Nektar Therapeutics offices?

    Nektar Therapeutics has offices in San Francisco, Huntsville and Secunderabad.

  • How many offices does Nektar Therapeutics have?

    Nektar Therapeutics has 3 offices.